Pfizer: collaboration and licensing agreement with Codex DNA

(CercleFinance.com) - Codex DNA announced that it has signed a collaboration and licensing agreement with Pfizer for its enzymatic DNA synthesis technology.


Under the terms of the agreement, Pfizer will have privileged access to Codex's "SOLA" technology, an approach for developing synthetic DNA, RNA or proteins.

This technique could facilitate the discovery of messenger RNA vaccines, new therapies, personalised drugs or other biopharmaceuticals, Codex said in a statement.

The terms of the deal were, which include an upfront payment from Pfizer, were not disclosed.


Copyright (c) 2022 CercleFinance.com. All rights reserved.